文献速递乳腺癌头颈与中枢神经肿瘤

乳腺癌脑转移瘤的同源重组缺陷评分高于配对原发肿瘤

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究利用已发表的21对配对原发/脑转移乳腺癌全外显子测序数据推导HRD相关突变特征,并在17对独立配对样本中用myChoice HRD检测验证。结果显示脑转移瘤中所有HRD相关突变特征均显著升高,验证队列中87.5%脑转移瘤HRD水平高于原发瘤,56%脑转移瘤为HRD阳性。提示脑转移瘤可能对PARP抑制剂更敏感。

要点

  • 乳腺癌脑转移瘤的HRD评分 consistently 高于配对原发肿瘤
  • 独立验证队列中87.5%脑转移瘤HRD水平升高,56%为HRD阳性
  • 脑转移瘤可能对PARP抑制剂治疗更敏感,需进一步研究

核心结论

  • 乳腺癌脑转移瘤相对于配对原发肿瘤表现出更高的HRD评分,提示脑转移瘤可能对PARP抑制剂更敏感。

研究设计与样本

  • 利用已发表的21对配对原发乳腺癌/脑转移瘤全外显子测序数据推导HRD相关突变特征评分。
  • 在17对独立配对原发/脑转移乳腺癌样本中进行myChoice HRD检测验证。

主要发现

  • 在已发表的全外显子测序数据集中,所有提示HRD的突变特征在脑转移瘤中相对于配对原发肿瘤均显著升高。
  • 在独立验证队列中,myChoice HRD检测显示87.5%的脑转移瘤HRD水平高于原发肿瘤。
  • 根据myChoice标准,56%的脑转移瘤为HRD阳性。

关键数值与推荐

  • myChoice HRD检测:验证队列中87.5%脑转移瘤HRD水平升高,56%为HRD阳性。

临床怎么用

  • 脑转移瘤HRD评分升高提示可考虑对乳腺癌脑转移患者评估PARP抑制剂治疗的潜在获益。
  • 需进一步研究其他转移部位是否也存在HRD升高,以及临床试验是否应调整HRD策略以优先选择PARP抑制剂治疗患者。

局限性

  • 研究基于回顾性配对样本分析,样本量有限(21对和17对)。
  • 需进一步验证其他转移部位是否同样存在HRD升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on its mechanism of action, PARP inhibitor therapy is expected to benefit mainly tumor cases with homologous recombination deficiency (HRD). Therefore, identification of tumor types with increased HRD is important for the optimal use of this class of therapeutic agents. HRD levels can be estimated using various mutational signatures from next generation sequencing data and we used this approach to determine whether breast cancer brain metastases show altered levels of HRD scores relative to their corresponding primary tumor. PATIENTS AND METHODS: We used a previously published next generation sequencing dataset of 21 matched primary breast cancer/brain metastasis pairs to derive the various mutational signatures/HRD scores strongly associated with HRD. We also carried out the myChoice HRD analysis on an independent cohort of 17 breast cancer patients with matched primary/brain metastasis pairs. RESULTS: All of the mutational signatures indicative of HRD showed a significant increase in the brain metastases relative to their matched primary tumor in the previously published whole exome sequencing dataset. In the independent validation cohort, the myChoice HRD assay showed an increased level in 87.5% of the brain metastases relative to the primary tumor, with 56% of brain metastases being HRD positive according to the myChoice criteria. CONCLUSIONS: The consistent observation that brain metastases of breast cancer tend to have higher HRD measures may raise the possibility that brain metastases may be more sensitive to PARP inhibitor treatment. This observation warrants further investigation to assess whether this increase is common to other metastatic sites as well, and whether clinical trials should adjust their strategy in the application of HRD measures for the prioritization of patients for PARP inhibitor therapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Diossy M, Reiniger L, Sztupinszki Z, et al. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol. 2018. PMID: 29917049. doi:10.1093/annonc/mdy216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。